Cohance Lifesciences Declines 9.39%: 5 Key Factors Behind the 52-Week Lows

2 March 2026: Stock Hits 52-Week Low at Rs.298 Amid Continued Downtrend

On the first trading day of the week, Cohance Lifesciences Ltd’s share price declined by 1.64% to close at Rs.303.70, touching an intraday low of Rs.298, marking a fresh 52-week low. This decline reflected ongoing challenges in the company’s financial performance, with the stock trading below all key moving averages, signalling sustained bearish momentum. The Sensex also fell 1.41%, but the stock underperformed the broader market and its sector peers by a notable margin.

Financially, the company reported a 61.2% drop in quarterly profit after tax (PAT) to Rs.40.19 crores and a 1.98% decline in net sales, continuing a negative trend over recent quarters. The full pledge of promoter shares added to market concerns, increasing the risk of forced selling in a declining market environment.

4 March 2026: Further Decline to Rs.296.5 Amid Sector Weakness

The downward trend continued on 4 March, with the stock closing at Rs.297.70, down 1.98% on the day and hitting a new 52-week low of Rs.296.5 intraday. This marked a cumulative loss of over 3% in two trading sessions. The Sensex declined 1.92% on the same day, but Cohance’s underperformance persisted, reflecting ongoing selling pressure.

Despite the negative price action, the company’s valuation metrics began to show signs of improvement. The price-to-book value ratio stood at 3.1, and the price-to-earnings ratio was 37.87, positioning the stock as more attractively valued relative to many sector peers. However, these valuation shifts were insufficient to counterbalance the negative sentiment driven by weak financial results and full promoter share pledging.

5 March 2026: Stock Falls to Rs.291.80; Valuation Upgrade Signals Price Attractiveness

On 5 March, the stock declined further by 1.98% to close at Rs.291.80, touching an intraday low of Rs.289.35, marking yet another 52-week low. This extended the three-day losing streak, with a cumulative decline exceeding 6%. The stock notably underperformed the Pharmaceuticals & Biotechnology sector by 4.01%, while the Sensex gained 1.29%.

Amid this price weakness, MarketsMOJO upgraded Cohance Lifesciences Ltd’s Mojo Grade from Strong Sell to Sell, reflecting a modestly more favourable outlook. The valuation shift from fair to attractive was driven by improved price-to-earnings and price-to-book ratios relative to peers such as J B Chemicals and Astrazeneca Pharmaceuticals, which trade at significantly higher multiples. Enterprise value multiples and profitability metrics also supported this upgrade, with a return on equity of 10.93% and return on capital employed of 13.36%.

6 March 2026: Week Closes at Rs.279.75, Marking Fresh 52-Week Low

The week ended with the stock hitting a new 52-week low of Rs.281.25 intraday and closing at Rs.279.75, down 4.13% on the day and 9.39% for the week. This marked a four-day consecutive decline, accumulating an 8.26% loss over that period. The stock underperformed its sector by 2.95% and the Sensex by 3.00% for the week.

Financially, the company’s quarterly profit before tax excluding other income fell 66.7% to Rs.39.30 crores, while PAT declined 61.2% to Rs.40.19 crores. Operating profit growth remains negative at an annualised rate of -1.40% over five years, and return on capital employed is subdued at 13.59%. The full pledge of promoter shares continues to weigh on market sentiment, exacerbating selling pressure amid the downtrend.

Daily Price Comparison: Cohance Lifesciences Ltd vs Sensex

Key Takeaways

Persistent Downtrend and Underperformance: Cohance Lifesciences Ltd’s stock price declined sharply by 9.39% over the week, significantly underperforming the Sensex’s 3.00% fall. The stock hit multiple 52-week lows, reflecting sustained bearish momentum and weak investor sentiment.

Financial Challenges: The company reported very negative quarterly results with a 61.2% decline in PAT and a 1.98% drop in net sales. Operating profit growth remains negative over five years, and return on capital employed is subdued, indicating ongoing profitability pressures.

Promoter Share Pledging: The full pledge of promoter shares (100%) remains a critical risk factor, potentially exacerbating selling pressure during market downturns and contributing to price volatility.

Valuation Improvements: Despite the downtrend, valuation metrics have shifted from fair to attractive, with a price-to-earnings ratio of 37.87 and price-to-book value of 3.1, comparatively lower than many sector peers. This has led to a Mojo Grade upgrade from Strong Sell to Sell, signalling a modestly more favourable analytical outlook.

Market and Sector Context: The Pharmaceuticals & Biotechnology sector and broader market also faced pressure during the week, but Cohance’s underperformance relative to both highlights company-specific challenges beyond general market weakness.

Conclusion

Cohance Lifesciences Ltd’s share price decline of 9.39% over the week to Rs.279.75 underscores a difficult period marked by weak financial results, sustained negative returns, and market concerns over promoter share pledging. While valuation metrics have improved, suggesting price attractiveness relative to peers, these have not yet translated into price recovery. The stock’s persistent underperformance relative to the Sensex and sector peers highlights ongoing operational and market challenges. Investors and market watchers will need to closely monitor upcoming financial disclosures and market developments to assess any potential shifts in the company’s trajectory.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today